The Pro Medicus (ASX:PME) share price is surging 5% on Thursday

This ASX biotech share is having a strong day of trade

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price is surging higher on Thursday. Shares in the Aussie biotech group have climbed more than 5% in a sharp rebound from Wednesday's session.

At the time of writing, the Pro Medicus share price is up 4.05%, trading at $54.71.

Group of medical professionals high five

Image source: Getty Images

What's with the Pro Medicus share price today?

Today's share price move hasn't been sparked by any news or announcements from the Aussie healthcare group. In fact, Pro Medicus hasn't released any ASX announcements at all since September 2.

However, that hasn't stopped investors piling into the company's shares and bidding up the Pro Medicus share price on Thursday.

It's possible today's moves are a rebound after shares in the ASX healthcare informatics group slumped lower yesterday. The company's shares have been under pressure amid broader weakness in the healthcare and technology sectors.

While yesterday had signs of profit-taking after year to date gains above 50%. Any fears of extended losses have subsided for now, however, as momentum has returned to the healthcare group's shares on Thursday.

A rising tide?

There is also the old 'rising tide raises all ships' adage that could be at play. The S&P/ASX 200 Index (ASX: XJO) has added 1.82% at the time of writing in a good day for Aussie investors.

Strong investor sentiment could be playing its part with the Pro Medicus share price roaring back to life after a disappointing day of trade on Wednesday.

It's yet another day of gains in what is shaping up to be a good year for shareholders. Despite somewhat stagnating earlier this year, the company's value has been steadily climbing since May.

Steady gains appear to have been supported by new contract signings including an 8-year, $14 million deal with The University of Vermont.

Foolish takeaway

It looks like the good times just keep on rolling for the Pro Medicus share price. Shares in the ASX biotech have now more than doubled in the last 12 months with gains of 104%.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »